Æterna Zentaris Propriété du management
Quel est le Propriété du management de Æterna Zentaris?
Le Propriété du management de Æterna Zentaris, Inc. est 0.34%
Quelle est la définition de Propriété du management?
La propriété d'un initié est calculée en divisant le nombre total d'actions possédées par des initiés (actionnaires détenant plus de 5% de la société ou un dirigeant ou un administrateur de la société) par le nombre total d'actions en circulation.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Propriété du management des entreprises dans Health Care secteur sur TSX par rapport à Æterna Zentaris
Que fait Æterna Zentaris?
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Entreprises avec propriété du management similaire à Æterna Zentaris
- The AES a Propriété du management de 0.33%
- Compass PLC a Propriété du management de 0.34%
- Western Forest Products a Propriété du management de 0.34%
- AXMIN a Propriété du management de 0.34%
- Western Forest Products a Propriété du management de 0.34%
- AES a Propriété du management de 0.34%
- Æterna Zentaris a Propriété du management de 0.34%
- China Environmental Investment a Propriété du management de 0.34%
- Noble Corp Plc a Propriété du management de 0.34%
- Toromont Industries a Propriété du management de 0.34%
- Alexion Pharmaceuticals a Propriété du management de 0.34%
- Marathon Petroleum Dl ,01 a Propriété du management de 0.34%
- Tortoise Pipeline & Fund Inc a Propriété du management de 0.34%